ABSTRACT BACKGROUND In the CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in New
These benefits persisted over the full duration of randomized follow-up (13) , were consistent in patients with both preserved and reduced ejection fraction (14) as well as Medicare-eligible subjects (15) , and were tightly linked to the achieved reduction in PAP with diuretic agents and other guideline-directed pharmacological therapies (16) . Based on these observations, in ANALYSIS OF EFFECTIVENESS. We compared rates of HFH (defined using the published CMS methodology [19] ) and all-cause hospitalization during the Table 1 .
Overall, for both cohorts, the mean age was 71 AE 11 years, with 40% of subjects at least 75 years of age, 36% women, 14% black race, and a large burden of comorbid medical illness, including diabetes, hypertension, and chronic obstructive pulmonary disease.
Clinical outcomes for the 6 months before and after implantation are summarized in Table 2 . Table 2) .
Clinical outcomes for the subset of patients with complete 12-month data available for the period before and after implantation are summarized in Values are mean AE SD or n (%). *Comorbidities identified using diagnosis codes from health care encounters in the 6 months before implant.
COPD ¼ chronic obstructive pulmonary disease; PAP ¼ pulmonary artery pressure.
Desai et al. The reduction in all-cause hospitalization was also sustained at 12 months (HR: 0.77; 95% CI: 0.70 to 0.86; p < 0.001), as were the reductions in total costs compared with the pre-implant interval ( Table 2) . Desai et al.
